SYNDEVRX INC

CAMBRIDGE, MA · Founded 2007 · CIK 0001455364 · Biotech · Private

Small molecule therapeutics targeting cancer metabolism and angiogenesis

syndevrx.com →
Grants
—
No SBIR or STTR on record
Sector median: 1
Raised
$38M
8 Form D · Nov 2024
23 months since last filing
Contracts
—
No federal contracts on record
Patents
40
18 granted · 22 pending
Sector median: 2

Capital Timeline

Federal above the line · equity below · node area scaled to amount
Capital and federal award history
DateEventSourceAmount
Private capital raisedForm D · SEC$569,659
Private capital raisedForm D · SEC$80,000
Private capital raisedForm D · SEC$15,000
Private capital raisedForm D · SEC$500,000
Private capital raisedForm D · SEC$500,000
Private capital raisedForm D · SEC$6,100,000
Private capital raisedForm D · SEC$29,354,820
Private capital raisedForm D · SEC$978,000
Form D · SEC

Peer position

Biotech · 4373 companies · ranked on federal contract value
Biotech companies ranked by federal contract value
#CompanyContractsDisclosed equity
2294Fortress Biotech, Inc.—$39M
2295Tortugas Neuroscience——
2296FutureDerm Inc.—$468K
2297SYNDEVRX INC—$38M
2298Zya, Inc.—$37M
2299Cyclacel Pharmaceuticals, Inc.—$36M
2300Retrotope, Inc.—$32M

Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.

Founders & Team

From Form D filings · 12 related persons
  • Bradley CarverDirector · Executive Officer
  • Michael CliffordDirector
  • Charles FlynnDirector
  • Charlie FlynnDirector
  • Richard LoveDirector
  • David NeafusExecutive Officer
  • John PetersenExecutive Officer
  • John PetersonExecutive Officer
  • Joanne SchindlerExecutive Officer
  • James ShanahanDirector · Executive Officer
  • Eric TookerDirector
  • Jeffrey WellesDirector

Patents

USPTO · 18 granted of 40

Regulatory activity · Biotech

Sector-level, not company-level

Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.